HOUSE RULES FOR THIS PAGE
____________________________________________
Our Facebook page is not the best place to discuss your adverse events or safety issues associated with your use of our products or treatments or other companies’ products or treatments. If you, or someone you know, have possibly experienced an adverse event while taking any Fresenius Medical Care North America product, please consult the person’s physician, pharmacist, or other healthcare professional immediately. Please also contact our product support line at 1-800-227-2572. You are also encouraged to report side effects of prescription drugs to the FDA. To do so, visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
While we welcome open conversations and the sharing of relevant experiences, all participants on our social media channels are expected to follow these guidelines.
• Show respect: please feel free to express your opinion, while respecting the opinions of others.
• Use clean language: do not use profanity or abusive language.
• Keep it relevant: please only post comments or material that is on topic.
• Avoid spam: please feel free to express your opinion. We ask – for the sake of all our users – that you don’t post the same content over and over.
• Post in English.
• Be safe and remember that social media is public. We caution you to not share your full name, email address, social media handles, phone number, address, place of work, etc. as doing so is at your own risk.
• Do not misrepresent information about Fresenius Medical Care North America or any Fresenius Medical Care North America subsidiary/business in any way.
• Do not represent or speak on behalf of Fresenius Medical Care North America or any Fresenius Medical Care North America subsidiary/business without authority to do so.
• Do not post marketing and/or PR messages promoting products or services.
• Do not repeatedly post personal or offensive comments about individual Facebook users or people working at Fresenius Medical Care North America as this may be considered harassment.
• Do not provide medical advice. You may share information about your experiences. Do not play the role of a health care professional on Fresenius Medical Care’s social media channels.
• Do not post information that violates patient privacy or safety.
If you have questions regarding medical advice or whether a medical treatment or product is appropriate for you or an individual patient, always seek the advice of your physician or other qualified health care provider. For more general questions, you can also contact us at: 844-898-0333 and we will appropriately direct your call.
This page does not provide medical advice, and the contents are made available to you for informational purposes only.
• This page does not provide medical diagnoses or recommendations regarding medical treatment.
• This page and the content appearing on this site are not substitutes for professional medical advice, diagnosis or treatment.
• Never disregard medical advice or delay in seeking it because of something you have read on this page.
• In an emergency, call 911 or your local emergency assistance number.
• In no event will Fresenius Medical Care be liable for any decision made or action taken in reliance upon the information provided through this page.
By commenting on this Facebook page, you are indicating that you have read, understand and agree to abide by the above House Rules. Fresenius Medical Care North America monitors this page and reserves the right to remove comments or discussion posts that are not in line with the House Rules or otherwise objectionable or inconsistent with the purpose of this page.
____________________________________________
Our Facebook page is not the best place to discuss your adverse events or safety issues associated with your use of our products or treatments or other companies’ products or treatments. If you, or someone you know, have possibly experienced an adverse event while taking any Fresenius Medical Care North America product, please consult the person’s physician, pharmacist, or other healthcare professional immediately. Please also contact our product support line at 1-800-227-2572. You are also encouraged to report side effects of prescription drugs to the FDA. To do so, visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
While we welcome open conversations and the sharing of relevant experiences, all participants on our social media channels are expected to follow these guidelines.
• Show respect: please feel free to express your opinion, while respecting the opinions of others.
• Use clean language: do not use profanity or abusive language.
• Keep it relevant: please only post comments or material that is on topic.
• Avoid spam: please feel free to express your opinion. We ask – for the sake of all our users – that you don’t post the same content over and over.
• Post in English.
• Be safe and remember that social media is public. We caution you to not share your full name, email address, social media handles, phone number, address, place of work, etc. as doing so is at your own risk.
• Do not misrepresent information about Fresenius Medical Care North America or any Fresenius Medical Care North America subsidiary/business in any way.
• Do not represent or speak on behalf of Fresenius Medical Care North America or any Fresenius Medical Care North America subsidiary/business without authority to do so.
• Do not post marketing and/or PR messages promoting products or services.
• Do not repeatedly post personal or offensive comments about individual Facebook users or people working at Fresenius Medical Care North America as this may be considered harassment.
• Do not provide medical advice. You may share information about your experiences. Do not play the role of a health care professional on Fresenius Medical Care’s social media channels.
• Do not post information that violates patient privacy or safety.
If you have questions regarding medical advice or whether a medical treatment or product is appropriate for you or an individual patient, always seek the advice of your physician or other qualified health care provider. For more general questions, you can also contact us at: 844-898-0333 and we will appropriately direct your call.
This page does not provide medical advice, and the contents are made available to you for informational purposes only.
• This page does not provide medical diagnoses or recommendations regarding medical treatment.
• This page and the content appearing on this site are not substitutes for professional medical advice, diagnosis or treatment.
• Never disregard medical advice or delay in seeking it because of something you have read on this page.
• In an emergency, call 911 or your local emergency assistance number.
• In no event will Fresenius Medical Care be liable for any decision made or action taken in reliance upon the information provided through this page.
By commenting on this Facebook page, you are indicating that you have read, understand and agree to abide by the above House Rules. Fresenius Medical Care North America monitors this page and reserves the right to remove comments or discussion posts that are not in line with the House Rules or otherwise objectionable or inconsistent with the purpose of this page.
Location: United States, Massachusetts, Waltham
Employees: 10001+
Phone: +1 781-699-9000
Founded date: 1996
Investors 1
| Date | Name | Website |
| - | WP Global ... | wpglobalpa... |
Mentions in press and media 23
| Date | Title | Description |
| 31.08.2022 | Conga Announces Winners of 2022 Inspire Awards at Annual Conga Connect Conference | BROOMFIELD, Colo. (PRWEB) August 31, 2022 Conga, the global leader in scalable Revenue Lifecycle Management solutions, announced the winners of the 2022 Inspire Awards at the annual Conga Connect Conference in Orlando. The awards acknowledg... |
| 07.07.2022 | Pharmacists 'ready to get to work' after new FDA authorization allows them to prescribe Pfizer's Covid-19 antiviral | March means college basketball madness, but also kidney health awareness. So Fresenius is connecting the two with a new campaign featuring former NBA star and kidney transplant recipient Sean Elliott. Elliott is serving as Fresenius’ head “... |
| 21.03.2022 | Fresenius Health Partners, InterWell Health, and Cricket Health Announce $2.4B Merger | What You Should Know: – Cricket Health is announcing today that it will merge with Fresenius Health Partners (the value-based care arm of Fresenius), and InterWell Health, to form the nation’s premier, value-based kidney care provider with ... |
| 11.03.2022 | US-funded Phlow's first round of essential generics headed to children's hospitals, but they're made with foreign APIs | US-based pharma manufacturer Phlow announced earlier this week that it would supply essential medicines over the next quarter to the Children’s Hospital Coalition, after collaboration with the group to identify the medicines that are at ris... |
| 11.03.2022 | Novavax aims for name recognition in new vaccines campaign | After suffering delay after delay, Novavax finally made it to the FDA back in January with its protein-based Covid-19 vaccine. But the Maryland-based company isn’t waiting for an authorization to get its name out there. Novavax launched two... |
| 11.03.2022 | Following Vraylar success, AbbVie extends partnership with Gedeon Richter to neuropsychiatric diseases | AbbVie is seeing dollar signs as it looks to expand the label on Vraylar, its Gedeon Richter-partnered antipsychotic blockbuster. And now, it wants to know what else the Hungarian pharma company has up its sleeve. After seeing some preclini... |
| 11.03.2022 | Senators call on CMS to finalize pharmacy fee reforms to save seniors $21B in out-of-pocket expenses | A bipartisan group of 30 US senators from both sides of the aisle sent a letter earlier this week to Chiquita Brooks-LaSure, head of the Centers for Medicare and Medicaid Services, urging her to finalize certain pharmacy fee reforms that co... |
| 02.02.2022 | Fresenius Medical Care : Kidney Care Launches Peritoneal Dialysis Training | Next Generation Patient Educational Experience Aims to Improve Successful Starts on Home Dialysis WALTHAM, Mass. -February 2, 2022 - Fresenius Kidney Care, the dialysis services division of Fresenius Medical Care North America (FMCNA), toda... |
| 25.01.2022 | KidneyCare:365 CKD Program Earns NCQA Accreditation | Population Health Program Supports Health Plan Members with Chronic Kidney Disease WALTHAM, Mass. - Jan. 25, 2022 -Fresenius Medical Care North America (FMCNA), a leading provider of kidney care products and services, announced today that i... |
| 13.01.2022 | Fresenius Medical Care : FKC Partners with Biim Ultrasound AS | Portable Ultrasound System Expands to Hundreds of Dialysis Centers to Assist Cannulation WALTHAM, Mass. & NARVIK, Norway - Jan. 13, 2022 - Fresenius Kidney Care, the nation's leading provider of kidney care services, and Biim Ultrasound... |
Show more